ALIVUS LIFE SCIENCES LIMITED
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockRule-based from financial data. Not advice.
Historically, Apr has averaged the highest return (+9.5%); Feb the lowest (-11.0%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +4.8%Positive MonthJan 2026: +4.81% | -5.0%Negative MonthFeb 2026: -5.02% | +6.7%Positive MonthMar 2026: +6.69% | +6.5%Positive MonthApr 2026: +6.50% | -0.1%Neutral MonthMay 2026: -0.15% | +11.6%Positive MonthJun 2026: +11.59% | -4.5%*Negative MonthJul 2026: -4.47% | β | β | β | β | β |
| 2025 | +22.3%Positive MonthJan 2025: +22.32% | -26.3%Negative MonthFeb 2025: -26.33% | +21.9%Positive MonthMar 2025: +21.91% | +1.7%Neutral MonthApr 2025: +1.67% | -4.8%Negative MonthMay 2025: -4.79% | -4.0%Negative MonthJun 2025: -4.05% | +2.8%Positive MonthJul 2025: +2.75% | -8.3%Negative MonthAug 2025: -8.33% | -1.6%Neutral MonthSep 2025: -1.60% | -2.5%Negative MonthOct 2025: -2.54% | -1.0%Neutral MonthNov 2025: -1.05% | +2.3%Positive MonthDec 2025: +2.34% |
| 2024 | +32.9%Positive MonthJan 2024: +32.86% | -0.5%Neutral MonthFeb 2024: -0.50% | -10.8%Negative MonthMar 2024: -10.75% | +6.9%Positive MonthApr 2024: +6.94% | +0.7%Neutral MonthMay 2024: +0.66% | +4.2%Positive MonthJun 2024: +4.18% | +2.2%Positive MonthJul 2024: +2.15% | +19.0%Positive MonthAug 2024: +19.04% | +0.1%Neutral MonthSep 2024: +0.10% | -0.5%Neutral MonthOct 2024: -0.52% | +3.2%Positive MonthNov 2024: +3.20% | -9.6%Negative MonthDec 2024: -9.55% |
| 2023 | -8.0%Negative MonthJan 2023: -8.04% | -3.1%Negative MonthFeb 2023: -3.12% | +4.5%Positive MonthMar 2023: +4.54% | +28.7%Positive MonthApr 2023: +28.73% | +6.8%Positive MonthMay 2023: +6.82% | +5.7%Positive MonthJun 2023: +5.74% | +16.5%Positive MonthJul 2023: +16.50% | -4.5%Negative MonthAug 2023: -4.50% | -2.5%Negative MonthSep 2023: -2.52% | +1.0%Neutral MonthOct 2023: +0.97% | +0.9%Neutral MonthNov 2023: +0.91% | +4.4%Positive MonthDec 2023: +4.43% |
| 2022 | -8.9%Negative MonthJan 2022: -8.93% | -20.2%Negative MonthFeb 2022: -20.25% | +0.1%Neutral MonthMar 2022: +0.14% | +3.5%Positive MonthApr 2022: +3.45% | -10.8%Negative MonthMay 2022: -10.85% | +4.7%Positive MonthJun 2022: +4.72% | +4.5%Positive MonthJul 2022: +4.51% | -5.1%Negative MonthAug 2022: -5.10% | -12.4%Negative MonthSep 2022: -12.37% | +10.4%Positive MonthOct 2022: +10.39% | +0.6%Neutral MonthNov 2022: +0.60% | -1.7%Neutral MonthDec 2022: -1.74% |
| 2021 | β | β | β | β | β | β | β | β | -1.6%Neutral MonthSep 2021: -1.55% | -6.8%Negative MonthOct 2021: -6.80% | -3.4%Negative MonthNov 2021: -3.45% | +3.2%Positive MonthDec 2021: +3.20% |
| AvgΒ±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position β all Januaries together, all Februaries together, and so on β to show whether a given month has leaned positive or negative historically. βSimpleβ counts each month as +1 or β1. βWeightedβ gives larger moves more influence: +2 above +10%, β2 below β10%. With only 6 years of history for this asset, each monthβs score reflects a small number of observations β read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the assetβs full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each dayβs closing price by the price on January 1st of that year (or the assetβs first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in βAverage fromβ, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ2.39 K Cr | β | βΉ486.00 Cr | β | β | 17.2% | 4.6% | 3.2% |
| Mar 2024 | βΉ2.28 K Cr | β | βΉ471.00 Cr | β | β | 20.2% | 5.6% | 0.9% |
| Mar 2023 | βΉ2.16 K Cr | β | βΉ467.00 Cr | β | β | 21.8% | 1.8% | 11.5% |
| Mar 2022 | βΉ2.12 K Cr | β | βΉ419.00 Cr | β | β | 20.4% | 12.6% | 19.0% |
| Mar 2021 | βΉ1.89 K Cr | β | βΉ352.00 Cr | β | β | 46.7% | 22.6% | 12.5% |
| Mar 2020 | βΉ1.54 K Cr | β | βΉ313.00 Cr | β | β | 77.9% | 73.5% | 59.7% |
| Mar 2019 | βΉ886.00 Cr | β | βΉ196.00 Cr | β | β | 222.7% | β | β |
| Mar 2018 | βΉ0.00 | β | βΉ0.00 | β | β | 0.0% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue / Net Sales | 0 | 886 | 1,537 | 1,885 | 2,123 | 2,161 | 2,283 | 2,387 | 2,481 |
| Total Expenses | 0 | 638 | 1,064 | 1,294 | 1,506 | 1,518 | 1,608 | 1,702 | 1,741 |
| EBIT / Operating Profit | 0 | 248 | 473 | 592 | 617 | 643 | 675 | 684 | 740 |
| OPM % | -4% | 28% | 31% | 31% | 29% | 30% | 30% | 29% | 30% |
| Other Income | 0 | 0 | 11 | 0 | 14 | 28 | 11 | 33 | 44 |
| Finance Costs | 0 | 1 | 34 | 88 | 28 | 1 | 2 | 2 | 4 |
| Depreciation & Amortisation | 0 | 19 | 29 | 33 | 38 | 42 | 53 | 61 | 67 |
| Profit Before Tax | 0 | 228 | 421 | 471 | 565 | 629 | 631 | 654 | 714 |
| Tax % | 4,200% | 14% | 26% | 25% | 26% | 26% | 25% | 26% | - |
| Net Profit / PAT | 0 | 196 | 313 | 352 | 419 | 467 | 471 | 486 | 530 |
| EPS (βΉ) | -430 | 997.86 | 1,597.37 | 358.74 | 34.17 | 38.11 | 38.43 | 39.63 | 43.27 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 61% | 110% | 59% | 13% | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| ALIVUS LIFE SCIENCES LIMITEDthis co. | βΉ10.78 K Cr | βΉ2.39 K Cr | 20.30 | 3.57 | 15.17 | 4.6% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |
